Non-small Cell Lung Cancer: Current Therapies and New Targeted Treatments
Conventional lung cancer treatments were once limited to surgery, radiation, and chemotherapy. However, gefitinib, a targeted drug, was launched in 2004, and the situation changed. Cancer cases that were highly responsive to gefitinib were later discovered to have epithelial growth factor receptor (...
Saved in:
Sonstige: | |
---|---|
Year of Publication: | 2021 |
Language: | English |
Physical Description: | 1 electronic resource (258 p.) |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
993545555104498 |
---|---|
ctrlnum |
(CKB)5400000000042934 (oapen)https://directory.doabooks.org/handle/20.500.12854/77051 (EXLCZ)995400000000042934 |
collection |
bib_alma |
record_format |
marc |
spelling |
Uchino, Junji edt Non-small Cell Lung Cancer: Current Therapies and New Targeted Treatments Non-small Cell Lung Cancer Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute 2021 1 electronic resource (258 p.) text txt rdacontent computer c rdamedia online resource cr rdacarrier Conventional lung cancer treatments were once limited to surgery, radiation, and chemotherapy. However, gefitinib, a targeted drug, was launched in 2004, and the situation changed. Cancer cases that were highly responsive to gefitinib were later discovered to have epithelial growth factor receptor (EGFR) mutations. This discovery opened the door for biomarker-based treatment strategies. Subsequently, several EGFR-tyrosine kinase inhibitors (TKI) were developed, and they became a new mainstay of treatment for non-small cell lung cancer. In recent years, many mechanisms of resistance to EGFR-TKI have been elucidated; a mutation in the T790M gene at exon 20 is found in half of the resistant cases. Hence, osimertinib, which specifically inhibits EGFR despite this T790M gene mutation, was developed to achieve long-term progression-free survival. Other driver mutations that are similar to the EGFR mutation were discovered, including the EML4-ALK fusion gene (discovered in 2007), ROS1 gene, and BRAF gene mutations. The TKIs for each of these fusion genes were developed and are used as therapeutic agents. Another advancement in advanced non-small cell lung cancer is the development of immune checkpoint inhibitors. Four PD-1/PD-L1 inhibitors, including nivolumab, are currently available for treatment of lung cancer. These drugs prevent an escape from the cancer immunity cycle. This ensures that cancer cells will express cancer antigens, causing an anticancer immune response. Due to cancer immunotherapy, long-term survival is possible. The biomarker development for cancer immunotherapy and its side effects are actively being studied. English Medicine bicssc non-small cell lung cancer previously treated patients phase I/II trial chemotherapy docetaxel S-1 immunotherapy rechallenge retrospective analysis pulmonary pleomorphic carcinoma prognostic factor glucose transporter 1 lung cancer multiple cancers metastasis sequencing mutation genomic diagnosis FDG-PET immune checkpoint inhibitor PD-1 prognosis RAD51B methylation PD-L1 expression predictive biomarker PD-1 blockade interstitial lung disease pulmonary fibrosis radiology and other imaging non-small-cell lung cancer epidermal growth factor receptor tyrosine kinase inhibitors TP53 mutations responsiveness targeted therapy network meta-analysis stage IIIA-N2 surgery immune checkpoint inhibitors biomarker nonsmall cell lung cancer HIP1R PD-L1 RUNX1 methylation survival EGFR-TKI T790M osimertinib immune-related adverse events endocrine disorders tumor-bearing patients PD-1 inhibitors PD-L1 inhibitors meta-analysis nivolumab Expanded Access Program real-world data daily practice prognostic factors NSCLC KRAS DNA polymerase beta platinum-based first-line adjuvant chemotherapy β-catenin lung neoplasms nucleotide-diphosphate kinase recurrence unresectable salvage surgery oligometastasis 3-0365-0130-4 3-0365-0131-2 Uchino, Junji oth |
language |
English |
format |
eBook |
author2 |
Uchino, Junji |
author_facet |
Uchino, Junji |
author2_variant |
j u ju |
author2_role |
Sonstige |
title |
Non-small Cell Lung Cancer: Current Therapies and New Targeted Treatments |
spellingShingle |
Non-small Cell Lung Cancer: Current Therapies and New Targeted Treatments |
title_full |
Non-small Cell Lung Cancer: Current Therapies and New Targeted Treatments |
title_fullStr |
Non-small Cell Lung Cancer: Current Therapies and New Targeted Treatments |
title_full_unstemmed |
Non-small Cell Lung Cancer: Current Therapies and New Targeted Treatments |
title_auth |
Non-small Cell Lung Cancer: Current Therapies and New Targeted Treatments |
title_alt |
Non-small Cell Lung Cancer |
title_new |
Non-small Cell Lung Cancer: Current Therapies and New Targeted Treatments |
title_sort |
non-small cell lung cancer: current therapies and new targeted treatments |
publisher |
MDPI - Multidisciplinary Digital Publishing Institute |
publishDate |
2021 |
physical |
1 electronic resource (258 p.) |
isbn |
3-0365-0130-4 3-0365-0131-2 |
illustrated |
Not Illustrated |
work_keys_str_mv |
AT uchinojunji nonsmallcelllungcancercurrenttherapiesandnewtargetedtreatments AT uchinojunji nonsmallcelllungcancer |
status_str |
n |
ids_txt_mv |
(CKB)5400000000042934 (oapen)https://directory.doabooks.org/handle/20.500.12854/77051 (EXLCZ)995400000000042934 |
carrierType_str_mv |
cr |
is_hierarchy_title |
Non-small Cell Lung Cancer: Current Therapies and New Targeted Treatments |
author2_original_writing_str_mv |
noLinkedField |
_version_ |
1796648759632855041 |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>04966nam-a2201165z--4500</leader><controlfield tag="001">993545555104498</controlfield><controlfield tag="005">20231214132828.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr|mn|---annan</controlfield><controlfield tag="008">202201s2021 xx |||||o ||| 0|eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)5400000000042934</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(oapen)https://directory.doabooks.org/handle/20.500.12854/77051</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)995400000000042934</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Uchino, Junji</subfield><subfield code="4">edt</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Non-small Cell Lung Cancer: Current Therapies and New Targeted Treatments</subfield></datafield><datafield tag="246" ind1=" " ind2=" "><subfield code="a">Non-small Cell Lung Cancer</subfield></datafield><datafield tag="260" ind1=" " ind2=" "><subfield code="a">Basel, Switzerland</subfield><subfield code="b">MDPI - Multidisciplinary Digital Publishing Institute</subfield><subfield code="c">2021</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 electronic resource (258 p.)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Conventional lung cancer treatments were once limited to surgery, radiation, and chemotherapy. However, gefitinib, a targeted drug, was launched in 2004, and the situation changed. Cancer cases that were highly responsive to gefitinib were later discovered to have epithelial growth factor receptor (EGFR) mutations. This discovery opened the door for biomarker-based treatment strategies. Subsequently, several EGFR-tyrosine kinase inhibitors (TKI) were developed, and they became a new mainstay of treatment for non-small cell lung cancer. In recent years, many mechanisms of resistance to EGFR-TKI have been elucidated; a mutation in the T790M gene at exon 20 is found in half of the resistant cases. Hence, osimertinib, which specifically inhibits EGFR despite this T790M gene mutation, was developed to achieve long-term progression-free survival. Other driver mutations that are similar to the EGFR mutation were discovered, including the EML4-ALK fusion gene (discovered in 2007), ROS1 gene, and BRAF gene mutations. The TKIs for each of these fusion genes were developed and are used as therapeutic agents. Another advancement in advanced non-small cell lung cancer is the development of immune checkpoint inhibitors. Four PD-1/PD-L1 inhibitors, including nivolumab, are currently available for treatment of lung cancer. These drugs prevent an escape from the cancer immunity cycle. This ensures that cancer cells will express cancer antigens, causing an anticancer immune response. Due to cancer immunotherapy, long-term survival is possible. The biomarker development for cancer immunotherapy and its side effects are actively being studied.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">English</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Medicine</subfield><subfield code="2">bicssc</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">non-small cell lung cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">previously treated patients</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">phase I/II trial</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">chemotherapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">docetaxel</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">S-1</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immunotherapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">rechallenge</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">retrospective analysis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">pulmonary pleomorphic carcinoma</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">prognostic factor</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">glucose transporter 1</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">lung cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">multiple cancers</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">metastasis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">sequencing</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">mutation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">genomic diagnosis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">FDG-PET</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immune checkpoint inhibitor</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">PD-1</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">prognosis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">RAD51B methylation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">PD-L1 expression</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">predictive biomarker</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">PD-1 blockade</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">interstitial lung disease</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">pulmonary fibrosis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">radiology and other imaging</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">non-small-cell lung cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">epidermal growth factor receptor</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tyrosine kinase inhibitors</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">TP53 mutations</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">responsiveness</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">targeted therapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">network meta-analysis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">stage IIIA-N2</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">surgery</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immune checkpoint inhibitors</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">biomarker</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">nonsmall cell lung cancer</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">HIP1R</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">PD-L1</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">RUNX1</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">methylation</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">survival</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">EGFR-TKI</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">T790M</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">osimertinib</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">immune-related adverse events</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">endocrine disorders</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">tumor-bearing patients</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">PD-1 inhibitors</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">PD-L1 inhibitors</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">meta-analysis</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">nivolumab</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Expanded Access Program</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">real-world data</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">daily practice</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">prognostic factors</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">NSCLC</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">KRAS</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">DNA polymerase beta</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">platinum-based first-line</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">adjuvant chemotherapy</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">β-catenin</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">lung neoplasms</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">nucleotide-diphosphate kinase</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">recurrence</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">unresectable</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">salvage surgery</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">oligometastasis</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-0365-0130-4</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-0365-0131-2</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Uchino, Junji</subfield><subfield code="4">oth</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-12-15 05:32:36 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2022-04-04 09:22:53 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="i">DOAB Directory of Open Access Books</subfield><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5337979050004498&Force_direct=true</subfield><subfield code="Z">5337979050004498</subfield><subfield code="b">Available</subfield><subfield code="8">5337979050004498</subfield></datafield></record></collection> |